Back

Select your region

Corporate

europe:

Flag Albania Albania Flag Bosnia and Herzegovina Bosnia and Herzegovina Flag Bulgaria Bulgaria Flag Croatia Croatia Flag Cyprus Cyprus Flag Montenegro Montenegro Flag Czech Republic Czech Republic Flag Denmark Denmark Flag Estonia Estonia Flag Spain Spain Flag Kosovo Kosovo Flag Lithuania Lithuania Flag Latvia Latvia Flag Luxembourg Luxembourg Flag Macedonia Macedonia Flag Germany Germany Flag Poland Poland Flag Portugal Portugal Flag Romania Romania Flag Serbia Serbia Flag Slovakia Slovakia Flag Slovenia Slovenia Flag Switzerland Switzerland Flag Sweden Sweden Flag Turkey Turkey Flag Hungary Hungary Flag United Kingdom United Kingdom Flag Italy Italy

Asia:

Flag UAE UAE Flag Hong Kong Hong Kong Flag Kuwait Kuwait Flag Lebanon Lebanon

Africa:

Flag South Africa South Africa

Schedule a cord blood consultation

Make an appointment

Contact us today!

Want to learn more about our services? Complete the form below and we will contact you as soon as possible to provide you with all the information you need and answer your questions.

    We kindly inform you that the personal data provided in the form will be processed by Polski Bank Komórek Macierzystych Sp. z o.o. ("PBKM") with its registered office in Warsaw, Al. Jana Pawła II 29 for telephone contact in connection with the provision of information on the service.

    Summary of patients treated

    Stem Cells
    Therapies

    Stem Cells Therapies

    The purpose of banking stem cells is to apply them in the therapy. For the first time cord blood was used in 1988 and since then according to publicly available statistics it has been used over 85 000 times worldwide (including statistics of China).

    FamiCord Group stores over 1,000,000 samples of cells of different types and has supplied stem cells for application in clinic for more than 7000 patients. We supply stem cells for standard transplantations (cord blood , bone marrow and mobilized peripheral blood) and cellular therapies. On top of that we provide cell based products in GMP standard for clinical trials.

    Stem cells manufactured in our premises helped patients with various diseases and therapeutic areas, including haematological, neurological, ophthalmological, orthopaedical, dermatological disorders.

    Check the full list of patients who received stem cell therapy derived from FamiCord labs.

    List last update: 06.2026

    List of patients who received stem cells from FamiCord Group laboratories

    List of patients who received stem cells from FamiCord Group laboratories
    Lp. Source Source type Diagnosis Medical field Year of application Therapy Country Age of recipient
    201 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Canada 69
    202 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Italy 66
    203 Apheresis Allogeneic Fanconi Anemia Hematology 2026 Standard Therapy Germany 4
    204 Apheresis Allogeneic Leukemia T-PLL Hematology 2026 Standard Therapy Norway 64
    205 Apheresis Allogeneic T-cell NHL Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy Germany 46
    206 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Germany 60
    207 Apheresis Allogeneic MM, Myeloma Multiplex Hematology 2026 Standard Therapy Poland 48
    208 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Norway 29
    209 Apheresis Allogeneic Myelofibrosis Myeloid Metaplasia Hematology 2026 Standard Therapy USA 27
    210 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Austria 34
    211 Apheresis Allogeneic Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes(MDS) Hematology 2026 Standard Therapy Poland 55
    212 Apheresis Allogeneic Thalassemia Major Hematology 2026 Standard Therapy Turkey 11
    213 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Norway 59
    214 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 75
    215 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Hungary 62
    216 Apheresis Allogeneic 2nd Myelodysplastic Syndrome Hematology 2026 Standard Therapy Netherlands 67
    217 Apheresis Allogeneic Acute Myelomonocytic Leukemia (AMML) Hematology 2026 Standard Therapy Ukraine 44
    218 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Portugal 59
    219 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Germany 54
    220 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy France 67
    221 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Spain 47
    222 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Hungary 42
    223 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Hungary 67
    224 Apheresis Allogeneic Prolymphocytic Leukemia Hematology 2026 Standard Therapy USA 66
    225 Apheresis Allogeneic Other Myelofibrosis/Myelosclerosis Hematology 2026 Standard Therapy USA 59
    226 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy USA 52
    227 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Australia 57
    228 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Australia 56
    229 Apheresis Allogeneic Chronic Myelomonocytic Leukemia (CMML) Hematology 2026 Standard Therapy Germany 56
    230 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Ukraine 37
    231 Apheresis Allogeneic Sickle Cell Anemia Hematology 2026 Standard Therapy Germany 10
    232 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 71
    233 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Canada 69
    234 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy France 51
    235 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 63
    236 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 65
    237 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy Sweden 68
    238 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Czechia 67
    239 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Spain 63
    240 Apheresis Allogeneic Chronic Lymphocytic Leukemia Hematology 2026 Standard Therapy Australia 57
    241 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 51
    242 Apheresis Allogeneic B-Cell Acute Lymphoblastic Leukemia (B-ALL) Hematology 2026 Standard Therapy Poland 46
    243 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 59
    244 Apheresis Allogeneic Primary Myelofibrosis (PMF) Hematology 2026 Standard Therapy Poland 59
    245 Apheresis Autologous T-cell Lymphoblastic Lymphoma Hematology 2026 Standard Therapy Germany 40
    246 Apheresis Autologous Anaplastic Large-Cell Lymphoma Hematology 2026 Standard Therapy Germany 68
    247 Apheresis Autologous Central Nervous System Lymphoma Hematology 2026 Standard Therapy Germany 51
    248 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 64
    249 Apheresis Allogeneic Acute Myeloid Leukemia Hematology 2026 Standard Therapy Germany 58
    250 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 63
    251 Apheresis Autologous T-Cell Lymphoma Hematology 2026 Standard Therapy Germany 68
    252 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 68
    253 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 65
    254 Apheresis Allogeneic Chronic Myeloid Leukemia Hematology 2026 Standard Therapy United Kingdom 55
    255 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Poland 65
    256 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Austria 43
    257 Apheresis Allogeneic Chronic Myelomonocytic Leukemia Hematology 2026 Standard Therapy USA 60
    258 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy Poland 58
    259 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy Spain 66
    260 Apheresis Allogeneic Myelodysplastic Syndrome IB2 Hematology 2026 Standard Therapy Germany 59
    261 Apheresis Allogeneic Myelofibrosis Myeloid Metaplasia Hematology 2026 Standard Therapy USA 63
    262 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Israel 74
    263 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 67
    264 Apheresis Allogeneic Serum Amyloid A (SAA) Hematology 2026 Standard Therapy United Kingdom 11
    265 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Germany 54
    266 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy India 52
    267 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy India 45
    268 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Spain 62
    269 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Netherlands 47
    270 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 58
    271 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Lithuania 63
    272 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy United Kingdom 56
    273 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy Germany 72
    274 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy United Kingdom 30
    275 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 69
    276 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 70
    277 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Ireland 73
    278 Apheresis Allogeneic Other Leukemia, Specify, Chronic Neutrophilic Leukemia Hematology 2026 Standard Therapy USA 56
    279 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy USA 60
    280 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Spain 64
    281 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 66
    282 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 33
    283 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Switzerland 69
    284 Apheresis Allogeneic CML Blast Crisis Hematology 2026 Standard Therapy Poland 38
    285 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy India 34
    286 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Bulgaria 49
    287 Apheresis Allogeneic Hodgkin lymphoma Hematology 2026 Standard Therapy Russian Federation 37
    288 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 65
    289 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 24
    290 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 58
    291 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 69
    292 Apheresis Allogeneic Chronic Lymphocytic Leukemia Hematology 2026 Standard Therapy Poland 63
    293 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Belgium 64
    294 Apheresis Allogeneic Myelofibrosis Hematology 2026 Standard Therapy Argentine 52
    295 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Spain 71
    296 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Australia 55
    297 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 75
    298 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 69
    299 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Poland 12
    300 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy USA 71